US-based medical technology company Bluegrass Vascular has secured CE Mark approval and is commercially launching its Surfacer Inside-Out Access Catheter System.
The Surfacer System is designed to provide central venous access for reliable and efficient catheter insertion into the central venous system, through an Inside-Out approach.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This patented approach enables the placement and maturation of permanent arteriovenous access options that promote improved patient results while reducing cost of care for both hospitals and hemodialysis providers.
According to Bluegrass Vascular founder and developer of the Inside-Out method John Gurley, the approach helps in restoring and preserving right-sided venous access in spite of chronic occlusion while sustaining the viability of other existing central veins.
The process involves the insertion of a Surfacer System through the femoral vein and navigating it up through the patient's venous system with an exit point in the right internal jugular vein, which serves as the optimal location for placing a central venous catheter.
Medical University of Vienna in Austria medicine, nephrology and intensive care medicine associate professor Gu¨rkan Sengo¨lge said: "The launch of the Surfacer System in Europe brings a much-needed solution to a growing population of patients requiring vascular access for vital treatments and who currently have limited options due to obstructed upper body access.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"I was very pleased with my first commercial use of the Surfacer System. No other device offers such an innovative Inside-Out method for restoring access and preserving options in patients with chronically occluded veins. Based on my initial experience, I am confident that the Surfacer System will change the standard of care going forward."
The company is also planning to begin enrolment for its Surfacer System to Facilitate Access in Venous Occlusions (SAVE) Study intended for patients with limited or diminishing upper body venous access or pathology impeding standard access methods.
